ANIXA BIOSCIENCES, INC. Increase (Decrease) in Deferred Revenue
ANIXA BIOSCIENCES, INC. (ANIX) reported Increase (Decrease) in Deferred Revenue of -$1.19 million for the 12-month period ending 2014-10-31, per its 10-K filed 2015-12-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2015-12-23
- ANIXA BIOSCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2014-10-31 was $0.00.
- ANIXA BIOSCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2012-10-31 was $0.00.
- ANIXA BIOSCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2012-07-31 was -$246.67K.
- ANIXA BIOSCIENCES, INC. increase (decrease) in deferred revenue for the quarter ending 2012-04-30 was -$246.67K.
- ANIXA BIOSCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2014 was -$1.19M.
- ANIXA BIOSCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2012 was -$940.01K, a 144.19% decline from fiscal 2011.
- ANIXA BIOSCIENCES, INC. increase (decrease) in deferred revenue for fiscal 2011 was $2.13M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2014-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-23 | -$1.19M 10-K · filed 2015-12-23 | ||
| 2014-07-31 | -$1.19M 10-Q · filed 2015-08-18 | |||
| 2012-10-31 | $0.00 derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2014-01-17 | -$246.67K derived: sum of 2 quarters · filed 2014-01-17 | -$493.34K derived: sum of 3 quarters · filed 2014-01-17 | -$940.01K 10-K/A · filed 2014-01-17 |
| 2012-07-31 | -$246.67K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2013-09-20 | -$493.34K derived: sum of 2 quarters · filed 2013-09-20 | -$940.01K 10-Q/A · filed 2013-09-20 | -$1.39M derived: sum of 4 quarters · filed 2013-09-20 |
| 2012-04-30 | -$246.67K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2013-06-19 | -$693.34K 10-Q/A · filed 2013-06-19 | -$1.14M derived: sum of 3 quarters · filed 2013-06-19 | |
| 2012-01-31 | -$446.67K 10-Q/A · filed 2013-03-25 | -$893.34K derived: sum of 2 quarters · filed 2013-03-25 | ||
| 2011-10-31 | -$446.67K derived: 10-K 12 month − 10-Q 9 month · filed 2013-01-29 | $2.13M 10-K · filed 2013-01-29 | ||
| 2011-07-31 | $2.57M 10-Q · filed 2012-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |